The 2011 United States (US) Committee on Fetus and Newborn guideline was released prior to the commercial availability of oral dextrose gel and so did not address their use for neonatal hypoglycemia, recommending intravenous glucose feeds instead. [1]
Subsequently, the 2019 Canadian Paediatric Society recommended dextrose 40% gel administered intrabuccal at 0.5 mL/kg for neonatal hypoglycemia as an alternative to IV therapy for asymptomatic infants with blood glucose <2.6 mmol/L in conjunction with enteral supplementation. However, this was recommended as a temporary measure in symptomatic infants until dextrose infusions could be started. [2]
In the Harris et al. Sugar Babies trial, dextrose gel was observed to have less treatment failures (success defined as blood glucose levels > 2.6 mmol/L after one/two dose) versus placebo (14% vs 24%; relative risk [RR] 0.57; 95% CI 0.33 to 0.98; p=0.04). Reduced neonatal admissions and supplementations needed from formulas were also observed for dextrose gels. It is recommended to administer with breastfeeding or formula. The 0.5 mg/kg dose should provide approximately 200 mg/kg of glucose which is equivalent to an IV bolus dose of 2 mL/kg of a D10W solution. [2], [3]
In 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) provided an extensive review of the efficacy of dextrose gel in neonatal hypoglycemia. Limited evidence gathered from the acquired systematic reviews found either beneficial or conflicting evidence in preventing neonatal hypoglycemia in at-risk patients. The data shows lack of evidence in reducing admission to neonatal ICU or special care, and adverse events seem to be similar versus placebo. [4]
Subsequent systematic reviews and meta-analyses have further confirmed the significant reduction in NICU admissions for symptomatic hypoglycemia with dextrose oral gel administration.
A Cochrane review evaluated the effects of dextrose gel in treating neonatal hypoglycemia. This analysis encompassed data from multiple randomized controlled trials, focusing on both the efficacy and safety profile of dextrose gel compared to placebo or no treatment at all. The primary outcome of interest was the normalization of blood glucose levels within a specified timeframe after gel administration. Secondary outcomes included neurodevelopmental implications at follow-up periods, ranging from infancy to early childhood. The studies collectively involved a diverse cohort of neonates, ensuring a robust representation of the target population. The findings highlighted a statistically significant improvement in glucose stabilization among neonates treated with dextrose gel compared to the control groups. The preferred formulation was oral dextrose gel (specifically 40% dextrose concentration) administered buccally. With regards to rates of adverse neurodevelopmental outcomes, there was no significant increase, suggesting a favorable safety profile for the gel's use in clinical practice. Importantly, these results underscore the potential of dextrose gel as a first-line intervention for managing neonatal hypoglycemia in at-risk late preterm and term infants, offering a straightforward application with minimal complications. [5]
A 2013 review examined the management strategies for neonatal hypoglycemia, particularly focusing on both transient and persistent forms. The review explored available therapeutic options such as dextrose infusions, glucagon, glucocorticoids, diazoxide, octreotide, and nifedipine. In general, there is a lack of a universally accepted threshold in defining neonatal hypoglycemia, though the authors suggest management of glucose levels under 50 mg/dL as hypoglycemic. Various treatments were discussed, such as the use of dextrose infusions to maintain euglycemia, especially in cases of hyperinsulinism, with glucagon and glucocorticoids recommended for acute management. Of the treatment options, diazoxide was highlighted as the first-line for hyperinsulinemic hypoglycemia and one of two available therapies which are available for oral use, though its efficacy is limited by genetic factors influencing insulin secretion. Octreotide was discussed as a secondary option, particularly if diazoxide fails, while oral nifedipine was noted as an investigational choice due to limited published data (see Table 1). [6]
A 2023 review conducted a thorough comparison of the most recent guidelines from major medical societies regarding the diagnosis and management of neonatal hypoglycemia (NH). This descriptive review scrutinized and synthesized recommendations from six influential organizations: the American Academy of Pediatrics (AAP), the British Association of Perinatal Medicine (BAPM), the European Foundation for the Care of the Newborn Infants (EFCNI), the Queensland Clinical Guidelines-Australia (AUS), the Canadian Pediatric Society (CPS), and the Pediatric Endocrine Society (PES). The analysis highlighted a significant consensus on the risk factors, clinical signs, and symptoms of NH, as well as the importance of early recognition and prompt treatment initiation to optimize outcomes. All organizations, except for the PES, recommended screening for NH in both asymptomatic high-risk and symptomatic newborns, though noted inconsistencies in screening approaches and operational thresholds for management, cut-off values, and treatment strategies. The review noted discrepancies among guidelines in defining NH, operational thresholds for intervention, and managing symptomatic and asymptomatic hypoglycemic neonates. Although the guidelines universally acknowledged the critical importance of preventing NH to avert potential brain injury and neurodevelopmental impairment, they differed in their definitions of NH and the cut-off glucose values warranting intervention. The AAP, AUS, and CPS identify a blood glucose level of less than 2.6 mmol/L (47 mg/dL) as a key operational threshold in the first 72 hours, while BAPM proposes a more conservative approach with different cut-off levels during the initial postnatal period. In asymptomatic NH, BAPM, EFCNI, and CPS recommend buccal administration of dextrose gel 40% at a dose of 200 mg/kg. [7]
A 2025 systematic review and meta-analysis examined the effectiveness of oral dextrose gel for managing neonatal hypoglycemia. This analysis synthesized data from five randomized controlled trials involving a total of 2,742 neonates, where 1,326 received oral dextrose gel and 1,416 were given a placebo. The primary focus was on reducing NICU admissions for neonates with blood glucose levels below 2.6 mmol/L. Initial findings from the meta-analysis indicated a non-significant reduction in NICU admissions (risk ratio 0.68; 95% confidence interval [CI] 0.33 to 1.38; p= 0.28). However, a sensitivity analysis excluding one outlier study revealed consistent and statistically significant results, showing a reduction in NICU admissions (risk ratio 0.52; 95% CI 0.31 to 0.90; p= 0.02), despite remaining substantial heterogeneity among studies. Despite variations across included trials, the evidence supports the potential clinical utility of oral dextrose gel to effectively manage neonatal hypoglycemia and reduce NICU admissions, presenting it as a valuable non-invasive alternative to intravenous interventions. [8]